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The host response to a virus is determined by intra-
cellular signaling pathways that are modified during
infection. These pathways converge as networks
and produce interdependent phenotypes, making
it difficult to link virus-induced signals and responses
at a systems level. Coxsackievirus B3 (CVB3) infec-
tion induces death of cardiomyocytes, causing
tissue damage and virus dissemination, through
incompletely characterized host cell signaling
networks. We built a statistical model that quantita-
tively predicts cardiomyocyte responses from time-
dependent measurements of phosphorylation
events modified by CVB3. Model analysis revealed
that CVB3-stimulated cytotoxicity involves tight
coupling between the host ERK and p38MAPK path-
ways, which are generally thought to control distinct
cellular responses. The kinase ERK5 requires p38
kinase activity and inhibits apoptosis caused by
CVB3 infection. By contrast, p38 indirectly promotes
apoptosis via ERK1/2 inhibition but directly causes
CVB3-induced necrosis. Thus, the cellular events
governing pathogenesis are revealed when virus-
host programs are monitored systematically and
deconvolved mathematically.
INTRODUCTION
Coxsackievirus B3 (CVB3) is among themost common causes of
viral myocarditis-associated heart failure in infants and young
children (Esfandiarei and McManus, 2008). A major component
of CVB3 pathogenesis is cell death of infected cardiomyocytes,
which leads to immediate tissue damage and the subsequent
release of virulent CVB3 progeny that furthers disease pro-
gression (Kawai, 1999). Intervening at the early stages of CVB3
cytotoxicity could potentially reduce the severity of the disease
and the need for heart transplantation in patients with viral
myocarditis.
Throughout infection, CVB3 modulates various cell-signaling
pathways that enable virus propagation (Esfandiarei and McMa-Cell Hnus, 2008; Garmaroudi et al., 2010). Inhibiting these pathways
may provide a therapeutic opportunity to restrict CVB3 patho-
genesis. But an important hurdle is our fragmentary under-
standing of how the CVB3 infection cycle intersects with the
host network. Viruses such as CVB3 have evolved to modulate
cell-signaling networks in ways that allow them simultaneously
to evade host defenses, promote cell entry, and undergo replica-
tion in a changing environment (Esfandiarei andMcManus, 2008;
Ribet and Cossart, 2010). Blocking individual signaling pathways
in host cells often reduces CVB3 infectivity but does not prevent
infection entirely (Garmaroudi et al., 2010). It remains unclear
whether such ‘‘partly required’’ pathways converge upon a com-
mon set of host effectors or instead make independent contribu-
tions to pathogenesis (Miller-Jensen et al., 2007). The challenge
is that CVB3 adaptively perturbs a collection of host pathways,
which must be examined concurrently with time to understand
how they interact and give rise to viral functions.
Here, we took a multipathway systems approach to connect
signaling and host-cell responses in an in vitro model of CVB3
infection (Tan et al., 2007). The dynamics of eight signaling
phosphoproteins were monitored together with six CVB3-
induced host-cell readouts at five different dosings of CVB3.
We then linked CVB3-induced signaling to host-cell readouts
by building a predictive data-driven model using two time-
dependent combinations of measured phosphoproteins. The
results of this analysis revealed unexpected connections
between the ERK1/2, ERK5, and p38 MAPK pathways related
to their control of apoptotic caspases and overall cell death
induced by CVB3. Combined perturbations of these pathways
validated the predictions of the model and deconstructed the
CVB3 response as a mixture of apoptosis (involving ERK5) and
necrosis (involving p38). Our results illustrate how viruses such
as CVB3 hijack multiple host signaling pathways simultaneously
but use relatively straightforward strategies to manipulate host
responses.RESULTS
CVB3-Induced Phosphoprotein DynamicsQuantitatively
Predict Host-Cell Outcomes
To determine whether known CVB3-induced signaling events
were sufficient to predict viral propagation and host-cell toxicity,
we sought to build a predictive mathematical model basedost & Microbe 13, 67–76, January 16, 2013 ª2013 Elsevier Inc. 67
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Figure 1. A Predictive Data-Driven Model of CVB3-Induced Host-Cell Responses
(A) Dynamic phosphoproteins signatures measured by phospho (p)-ELISA that were used as predictor variables in the data-driven model.
(B) Host-cell outcomes that were to be predicted in the data-driven model. Caspase (casp)-3, caspase-8, and caspase-9 activities were measured by activity
assays with fluorogenic substrates; VP1 capsid protein expression wasmeasured by immunoblotting; released viral progeny (RVP) titer wasmeasured by plaque
assay; and cell death wasmeasured byMTS assay at the indicated time points. All outcome data were nondimensionalized as Z scores for comparison of relative
changes across conditions.
(C and D) Accurate predictions of host-cell responses with a partial least-squares model using two principal components. (C) Percentage of information captured
with one or two principal components. Information was measured by the percentage of variance in host-cell outcomes that was captured by the model. Note the
small-but-detectable increase in information capture after inclusion of the second principal component (dashed arrow). (D) Correlation between crossvalidated
predictions of biological responses by partial least-squares regression (x axis) and observed biological responses (y axis). Marker color corresponds to the
postinfection (p.i.) time point at 8 hr (white), 16 hr (gray), and 24 hr (black).
HL1 cells were infected with CVB3 at one of five multiplicities of infection and then assessed for the indicated phosphoproteins and biological responses at six
and three time points, respectively, over 24 hr. For (A) and (B), data are shown as the Z score standardizedmean of three independent experiments as described in
the Experimental Procedures. For (C), data are shown as median information captured (red) after 5-fold leave-one-out crossvalidation (black). For (D), data are
shown as the median ± range of three to four biological replicates (vertical) or four model crossvalidation runs (horizontal). See also Figure S1 and Table S1.
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ERK-p38 Coordination of CVB3-Induced Cell Deathentirely on quantitative experiments. Data-driven modeling
identifies higher-order statistical covariations that can be used
for prediction and analysis (Janes and Yaffe, 2006). Unlike
other modeling formalisms (Aldridge et al., 2006), data-driven
approaches can accommodate variegated data sets and make
predictions without detailed knowledge of the underlying
biochemical mechanisms.
To build the model, we systematically assembled a host-cell
signaling and response data set in virus-infected cardiomyo-
cytes. At five different CVB3 multiplicities of infection (moi), we
profiled eight signaling phosphoproteins by ELISA at six time
points over 24 hr together with six CVB3-induced host-cell read-
outs at three time points over 24 hr (Figures 1A and 1B). Each
phosphoprotein and host-cell readout was selected based on
previous studies suggesting that they were critical for CVB3
pathogenesis (see Table S1 online). Analyzing the information
contained in this mechanism-rich signature would then allow68 Cell Host & Microbe 13, 67–76, January 16, 2013 ª2013 Elsevier Ius to examine how host-cell pathways were coordinately per-
turbed during CVB3 infection.
We found that CVB3-induced host-cell responses showed
time and dose dependencies that were expected for end-
stage readouts (Figure 1B). Activation of the initiator caspases,
caspase-8 and caspase-9, was accelerated with increasing
moi, corresponding to more-complete activation of the effector
caspase for apoptosis, caspase-3 (Riedl and Shi, 2004). Interest-
ingly, readouts of CVB3 propagation, such as expression of the
VP1 capsid protein and the titers of released viral progeny (RVP),
did not accelerate appreciably as they increased with CVB3moi.
This finding suggests intrinsic limits to the timing of the CVB3
replication cycle downstream of the moi-dependent rate
processes of viral docking and internalization. The pattern of
overall CVB3 cytotoxicity fell in between that of caspase and
viral readouts, showing some acceleration as host-cell viability
dropped with increasing CVB3 titers. Thus, CVB3 infection ofnc.
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ERK-p38 Coordination of CVB3-Induced Cell Deathcardiomyocytes elicits a collection of host-cell and viral pheno-
types that are monotonic in time but differ in their kinetics and
dose-dependent behaviors.
By comparison, we found that the dynamic patterns of protein
phosphorylation stimulated by CVB3 were substantially more
complex than the associated phenotypic readouts (Figures 1A
and 1B). As before, we observed accelerated phosphorylation
of some CVB3-induced pathways with increasing moi, such
as p38 and Hsp27, but not others, such as ERK (Figure 1A). In
addition, biphasic activation patterns were common, and many
individual activation peaks appeared or disappeared above a
critical threshold of CVB3 moi (e.g., ATF2, CREB, and IkBa).
Sham infection with 0 moi did not lead to any meaningful
changes when compared to 0.5 moi (Figure S1), confirming
that the measured signaling events were due to CVB3 infection.
The internal consistency of our phospho (p)-ELISA measure-
ments was also verified by the strong correlations between
p-Akt and p-GSK3b (R = 0.6), a direct substrate of Akt (Cross
et al., 1995), and between p-p38 and p-Hsp27 (R = 0.8), a direct
substrate of the MK2 kinase that is a substrate of p38 (Rouse
et al., 1994). The p-ELISA signatures thus provided a reliable
starting point for connecting CVB3-induced signaling to host-
cell outcomes.
One way that the observed CVB3-induced pattern of readouts
could be coordinated is if each phosphoprotein contributed
incrementally to the pattern based on its extent of phosphoryla-
tion. Host cells would then ‘‘integrate’’ the intracellular state
established by the level of CVB3 infection and gauge their
responses accordingly. To test the feasibility of this network
mechanism, we used partial least-squares modeling to link
linear combinations of measured phosphoproteins to observed
CVB3-induced readouts (Janes et al., 2005; Janes and Yaffe,
2006). In a partial least-squares model, linear combinations
take the form of principal components, which are latent
dimensions in the underlying data set that are derived to be
optimally efficient at predicting response outcomes (Jensen
and Janes, 2012).
To build the model, we first subdivided the phosphoprotein
time courses into early (0–8 hr) and late (8–24 hr) phases
and then time integrated each early and late phosphoprotein
measurement for every CVB3 moi. This subdivision allowed
us to separate biphasic activation profiles into early and late
peaks. Using the phosphoprotein data as a set of predictor
variables, we next sought a partial least-squares model that
could predict all of the CVB3-induced readouts accurately
and simultaneously. We found that a model with the two
leading principal components could capture all of the mea-
sured readouts to within 97% accuracy (Figure 1C). Impor-
tantly, this model also accurately predicted readouts for
individual moi conditions that were left out of the model training
during crossvalidation (Figure 1D). The model thus supported
a network mechanism in which multiple intracellular pathways
work together by independently contributing to CVB3-induced
readouts.
Intracellular Crosstalk between the ERK and p38
Pathways
Principal components can be further analyzed by plotting the
weighted linear combinations of the original measurementsCell Hthat provided the basis for accurate model predictions (Fig-
ure 2A) (Janes et al., 2005; Janes and Yaffe, 2006; Jensen and
Janes, 2012). In this mapping, early and late phosphoproteins
are depicted together with CVB3-induced readouts. Clusters of
phosphoproteins and readouts indicate measurements with
close association in principal-component space and highlight
correlations in the data that are most worthy of follow-up exper-
iments (Janes et al., 2006; Jensen and Janes, 2012).
Inspection of this principal-component mapping revealed that
all CVB3-induced readouts were densely clustered in one
region (Figure 2A, contours), suggesting that they were tightly
coupled. Within the cluster lay the transcription factor ATF2,
which is critical for CVB3 pathogenesis in vivo (Reimold et al.,
2001), and p38, a MAPK that we recently showed is the domi-
nant ATF2 kinase during CVB3 infection (Garmaroudi et al.,
2010). We also found p-Hsp27 in the cluster, which was ex-
pected because of its strong concordance with p-p38 (see
above). Conversely, we were surprised to find p-ERK located
in the cluster together with p-p38, because the ERK1/2 and
p38 pathways are generally thought to be activated by distinct
stimuli and often serve antagonistic functions (Xia et al., 1995).
Nevertheless, their tight association in the model suggested
that ERKs and p38 might be functionally interlinked during
CVB3 infection.
An important consideration for this prediction was the high-
throughput data upon which the model was founded (Janes
and Yaffe, 2006). The commercial p-ELISA used to assemble
the p-ERK data set is marketed as specific for ERK1/2. However,
ERK1 and ERK2 share 50% identity with ERK5, a third MAPK
whose regulation is distinct (Nishimoto and Nishida, 2006). All
three ERKs have a Thr-Glu-Tyr motif that is bis-phosphorylated
upon activation, and the sequence surrounding this motif is so
similar that many p-ERK1/2 antibodies will crossreact with
ERK5 (K.J.J. and K.A.J., unpublished data). p-ERK5 crossreac-
tivity is readily distinguished from p-ERK1/2 during immunoblot-
ting (ERK580–100 kDa versus ERK144 kDa, ERK242 kDa),
but the ELISA format cannot resolve proteins by molecular
weight. Because ERK5 signaling is important for cardiovascular
tissues (Regan et al., 2002), we decided to investigate the indi-
vidual contributions of ERK1/2 and ERK5 by independent
methods.
We first monitored the kinetics of ERK1/2 and ERK5 phos-
phorylation by blotting with antibodies that were specific for
each pathway (Figure 2B). Both ERK1/2 and ERK5 were strongly
phosphorylated shortly after CVB3 infection at 0.17 hr p.i. and
also after host cytotoxicity was evident at 24 hr p.i. However,
ERK5 showed a more-sustained phosphorylation up to 1 hr
p.i., and p-ERK1/2 exhibited a second peak at 8 hr p.i., illus-
trating differences in their regulatory kinetics. The multiphase
activation of ERK1/2 was further confirmed by measuring phos-
phorylation of RSK, a specific ERK1/2 substrate (Figure S2A)
(Sturgill et al., 1988). Next, we used a pair of MEK inhibitors
(PD184352 [PD] and U0126 [U0]) to separate the ERK1/2 and
ERK5 contributions to the ERK p-ELISA. PD at low concentra-
tions selectively blocks MEK1/2 and ERK1/2 phosphorylation,
whereas U0 inhibits MEK1/2–ERK1/2 and MEK5–ERK5 equally
(Davies et al., 2000) (Figures S2B and S2C). Thus, the contribu-
tion of ERK5 can be inferred from the difference between PD
(ERK1/2 inhibition) and U0 (ERK1/2 + ERK5 inhibition). Whenost & Microbe 13, 67–76, January 16, 2013 ª2013 Elsevier Inc. 69
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Figure 2. Model Principal Components
Identify Crosstalk between ERK and p38
Pathways
(A) Model projections of early phosphoproteins (0–
8 hr p.i., circles), late phosphoproteins (8–24 hr
p.i., clubs), and host-cell responses (contours)
onto the principal components derived in Fig-
ure 1C.
(B) Dynamics of phospho (p)-ERK1/2 and p-ERK5
over a 24 hr time course of CVB3 infection. HL1
cells were infected with CVB3 at moi = 9 and then
assessed for p-ERKs at the indicated times p.i. by
immunoblotting with tubulin used as a loading
control.
(C) ERK p-ELISA measurements are a convolution
of p-ERK1/2 and p-ERK5. HL1 cells were pre-
treated with DMSO, PD to inhibit p-ERK1/2, or U0
to inhibit p-ERK1/2 and p-ERK5 and then infected
with sham or CVB3 at moi = 9. The p-ERK signals
were assessed by p-ELISA at 0.17 hr p.i.
(D and E) Early- and late-phase activation of p-
p38, p-ERK1/2, and effector kinases upon
pretreatment with SB and infection with CVB3.
(F) Densitometry of late-phase p-ERK1/2 in
response to SB.
(G) Prolonged SB inhibition leads to ERK1/2
phosphorylation independently of CVB3 infection.
(H and I) Early- and late-phase phosphorylation of
ERK5 is blocked upon pretreatment with SB and
infection with CVB3.
(J) Densitometry of late-phase p-ERK5 in
response to SB.
For (D)–(J), HL1 cells were pretreated with
SB203580 (SB, 20 mM) for 1 hr, infected with sham
or CVB3 at moi = 9, and then assessed for phos-
phoproteins at the indicated times postinfection
by immunoblotting with either tubulin or b-actin
used as a loading control. For (C), (F), and (J), data were normalized to CVB3-infected cells without inhibitor and are shown as the mean ± SEM of three (C) or four
(F and J) biological replicates. Asterisk indicates p < 0.05 by Welch’s one-sided t test. See also Figure S2.
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ERK-p38 Coordination of CVB3-Induced Cell Deathcells were preincubated with U0 and treated with CVB3 for
10 min, we found that the measured p-ERK ELISA signal was
reduced to background levels (Figure 2C). By contrast, pretreat-
ment with PD reduced the ELISA signal by only 30%, even
though ERK1/2 phosphorylation was completely inhibited (Fig-
ure 2C and Figure S2C). This indicated that the p-ERK ELISA
data were a convolution of ERK1/2 and ERK5 pathway activities
and further implied that the predicted ERK-p38 associations
(Figure 2A) could be between ERK1/2 and p38 or ERK5 and
p38, or both.
We tested for crosstalk between p38 and ERKs by using
SB203580 (SB), an ATP-competitive small-molecule inhibitor of
p38 (Lee et al., 1994). We monitored p-ERK1/2, p-ERK5, and
p-p38, as well as the major ERK1/2 and p38 effector kinases,
RSK and MK2 (Rouse et al., 1994; Sturgill et al., 1988). We found
that SB potently inhibited p38 activity in cardiomyocytes, as ex-
pected, blocking phosphorylation of MK2 at early and late times
after CVB3 infection (Figures 2D and 2E). Acute SB treatment
was also specific, because we did not observe any effect on
early CVB3-induced ERK1/2 phosphorylation or activity (Fig-
ure 2D). Upon prolonged SB treatment, however, we observed
a modest-but-reproducible increase in ERK1/2 phosphorylation
(Figures 2E and 2F). We attribute this to secondary inhibition of70 Cell Host & Microbe 13, 67–76, January 16, 2013 ª2013 Elsevier IPP1 and PP2A phosphatases, which are normally activated by
p38 signaling and serve to dephosphorylate MEK1/2 upstream
of ERK1/2 (Westermarck et al., 2001). Subsequent control
experiments showed that SB-induced upregulation of ERK1/2
was independent of CVB3 treatment (Figure 2G). Thus, p38
signaling antagonizes late ERK1/2 signaling, prompting a re-
evaluation of earlier p38-inhibition experiments involving CVB3
(see below) (Si et al., 2005).
A second finding from these experiments was that SB treat-
ment potently blocked both early- and late-phase phosphoryla-
tion of ERK5 (Figures 2H–2J). The p38-ERK5 coupling was
consistent with predictions of the model (Figure 2A), but such
crosstalk had not previously been reported. To exclude the
possibility that ERK5 inhibition was caused by off-target effects
of SB, we repeated the experiments with BIRB796 (BIRB), an
allosteric inhibitor of p38 (Pargellis et al., 2002) (Figure S2D).
SB and BIRB have completely different mechanisms of inhibition
and off-target signatures; therefore, a common phenotype with
SB and BIRB strongly implicates p38 signaling (Bain et al.,
2007). When cardiomyocytes were pretreated with BIRB, we
observed the same blockade of CVB3-induced ERK5 phosphor-
ylation as with SB (Figures S2E and S2F). Last, to examine the
generality of the p38-ERK5 connection, we treated humannc.
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Figure 3. ERK5 Inhibits CVB3-Induced Apoptosis
(A) XMD inhibits ERK5 activity in cells. Samples were analyzed for phospho-
MEF2A at 24 hr p.i. by immunoblotting with tubulin as a loading control.
(B) CVB3-induced caspase-9 and caspase-3 processing is increased by XMD-
mediated inhibition of ERK5.
(C and D) Knockdown of endogenous ERK5 increases CVB3-induced cas-
pase-3 cleavage. HL1 cells were transduced with the indicated shRNAs and
analyzed for the indicated proteins by immunoblotting with tubulin or full-
length caspase-3 used as a loading control. In (D), quantitative densitometry is
shown relative to shGFP control cells infected with CVB3 at moi = 9.
(E) DOX induction of MEK5-DD activates endogenous ERK5. HL1 cells stably
expressing doxycycline (DOX)-inducible MEK5-DD were treated with 1 mg/ml
DOX for 24 hr and analyzed for the indicated proteins by immunoblotting with
tubulin used as a loading control.
(F) CVB3-induced caspase-8 and caspase-3 processing is decreased upon
activation of ERK5 by DOX-inducible MEK5-DD.
For (A) and (B), HL1 cells were pretreated with XMD8-92 (XMD, 5 mM) for 1 hr
and infected with sham or CVB3 at moi = 9. For (E) and (F), HL1 cells stably
expressing doxycycline (DOX)-inducibleMEK5-DDwere infectedwith CVB3 at
moi = 1.5 and treated with 1 mg/ml DOX at 0 hr p.i. Samples were analyzed for
the indicated active caspase-cleavage products at 24 hr p.i. by immunoblot-
ting with tubulin or full-length caspases used as a loading control. For (B) and
(F), densitometry measurements were normalized to sham-infected cells
without inhibitor, and data are shown as the mean ± SEM of four biological
replicates. Asterisk indicates p < 0.05 by Welch’s one-sided t test. See also
Figure S3.
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ERK-p38 Coordination of CVB3-Induced Cell Deathembryonic kidney cells with sorbitol as an osmotic stress that
activates both p38 and ERK5 (Abe et al., 1996; Raingeaud
et al., 1995). SB and BIRB each blocked hyperosmolarity-
induced ERK5 phosphorylation (Figure S2G), suggesting that
p38 is generally required for proper activation of the MEK5-Cell HERK5 pathway. Taken together, the molecular consequences
of SB and BIRB indicate that p38 is functionally interconnected
with both ERK1/2 and ERK5, as predicted by the model of
CVB3 pathogenesis (Figure 2A).
Deconvolution of the ERK- and p38-Dependent
Apoptotic Response
An important category of host-cell responses in the starting data
set was the activity of apoptotic caspases (Figure 1B). ERKs and
p38 mapped closely to these readouts in the model and could
conceivably control CVB3-induced apoptosis directly (Fig-
ure 2A). Both ERK1/2 and p38 have been reported to be impor-
tant for proper caspase activation (Luo et al., 2002; Si et al.,
2005). However, these earlier studies used a dual MEK1/2-
MEK5 inhibitor (U0) and were not aware of the antagonism
between p38 and ERK1/2 (Figures 2E–2G and Figure S2C). We
thus pursued follow-up studies using gain- and loss-of-function
approaches for ERK-p38 together with direct measurements of
caspase processing.
We began with ERK5, as it inhibits cardiac apoptosis in other
contexts (Kimura et al., 2010; Yan et al., 2007) but had not been
previously implicated in CVB3 infection. To block ERK5 sig-
naling, we used the specific ATP-competitive ERK5 inhibitor,
XMD8-92 (XMD) (Yang et al., 2010). XMD treatment potently
reduced phosphorylation of an ERK5 substrate (MEF2A) in cardi-
omyocytes and significantly increased caspase-9 and caspase-
3 cleavage upon CVB3 infection (p < 0.05) (Figures 3A and 3B).
CVB3-induced apoptosis also increased when endogenous
ERK5 was downregulated with shRNA (Figures 3C and 3D).
We performed a reciprocal gain-of-function experiment by es-
tablishing stable lines expressing a doxycycline (DOX)-inducible
mutant of MEK5 that was constitutively active (MEK5-DD) (Fig-
ure 3E). Upon low-level infection with CVB3 (moi = 1.5), we found
that DOX treatment of MEK5-DD-expressing cells caused a
significant decrease in caspase-3 cleavage (p < 0.05) (Figure 3F).
Interestingly, the drop in caspase-3 cleavage was associated
with changes in caspase-8 activation rather than caspase-9
activation as with XMD. We attribute this difference to the
kinetics of ERK5 activation with MEK5-DD (8 hr) versus ERK5
inhibition with XMD (<1 hr). The MEK5-DD, XMD, and shRNA
results together indicate that CVB3-induced ERK5 signaling
inhibits cardiomyocyte apoptosis. This link between ERK5 and
host-cell survival is unique, because virtually all other CVB3-
stimulated pathways described thus far promote apoptosis
rather than inhibit it (Table S1).
Next, we examined the p38 pathway by using a similar set of
approaches. Consistent with an earlier report (Si et al., 2005),
we found that p38 inhibition via SB profoundly reduced cas-
pase-3 cleavage during CVB3 infection (Figure 4A). We rein-
forced the SB result by showing that p38 inhibition with BIRB
phenocopied SB in its blockade of initiator and effector cas-
pases (Figures S4A andS4B). The intuitive conclusion from these
experiments is that p38 promotes CVB3-induced apoptosis.
However, when we attempted the reciprocal gain-of-function
experiment with a DOX-inducible, constitutively active mutant
ofMKK6 (MKK6-EE), therewas no detectable change in caspase
activation (Figures 4B and 4C). The apparent contradiction
prompted us to re-evaluate our experiments considering the
crosscommunication between p38 and ERKs (Figures 2E–2J).ost & Microbe 13, 67–76, January 16, 2013 ª2013 Elsevier Inc. 71
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Figure 4. p38 Inhibition Blocks CVB3-Induced Apoptosis Indirectly
via ERK1/2 Hyperactivation
(A) CVB3-induced caspase processing is blocked by SB-mediated inhibition of
p38.
(B–D) p38 activation via DOX-inducible MKK6-EE does not affect CVB3-
induced apoptosis but suppresses ERK1/2 phosphorylation. For (B) and (D),
HL1 cells stably expressing doxycycline (DOX)-inducible MKK6-EE were
treated with 1 mg/ml DOX for 8 hr and analyzed for the indicated proteins by
immunoblotting with tubulin used as a loading control.
(E) SB-mediated inhibition of caspase processing is blocked by coinhibition of
ERK1/2 signaling with PD.
(F) ERK1/2 inhibition with PD does not affect CVB3-induced apoptosis.
For (A), (E), and (F), HL1 cells were pretreated with SB203580 (SB, 20 mM),
PD184352 (PD, 2 mM), or SB+PD for 1 hr and infected with sham or CVB3 at
moi = 9. For (C), HL1 cells stably expressing DOX-inducible MKK6-EE were
infected with CVB3 at moi = 1.5 and treated with 1 mg/ml DOX at 8 hr
p.i. Samples were analyzed for the indicated active caspase-cleavage prod-
ucts at 24 hr p.i. by immunoblotting with tubulin or full-length caspases used as
a loading control. Densitometry measurements were normalized to sham-in-
fected cells without inhibitor, and data are shown as the mean ± SEM of four
biological replicates. Asterisk indicates p < 0.05 by Welch’s one-sided t test.
See also Figure S4.
Cell Host & Microbe
ERK-p38 Coordination of CVB3-Induced Cell DeathWe reasoned that secondary inhibition of ERK5 would partially
offset the observed SB-BIRB phenotype rather than cause it
(Figures 2H–2J and Figure 3). Therefore, our attention turned to
ERK1/2, which becomes hyperactivated upon prolonged p38
inhibition (Figures 2F and 2G). This negative regulation of72 Cell Host & Microbe 13, 67–76, January 16, 2013 ª2013 Elsevier IERK1/2 by p38 was further strengthened by the reduced
p-ERK1/2 observed in DOX-treated MKK6-EE cells (Figure 4D).
To determine whether the consequences of p38 inhibition
were mediated through ERK1/2, we combined SB with PD to
block ERK1/2 hyperactivation and found that CVB3-induced
apoptosis occurred normally (Figure 4E and Figure S4C).
Remarkably, ERK1/2 inhibition by itself did not substantially
affect apoptosis of CVB3-infected cells (Figure 4F and Fig-
ure S4C), suggesting that ERK1/2 acted as a prosurvival signal
only when p38 function was blocked. The p38-specific role of
ERK1/2 was re-emphasized in ERK5-inhibited cells, where PD+-
XMD increased apoptosis as with XMD alone (Figure 3B, Figures
S3A and S3B). Upon this re-evaluation of earlier studies using SB
(Si et al., 2005), we conclude that p38 signaling does not directly
control CVB3-induced apoptosis.
p38 Signaling Contributes to CVB3-Induced
Pathogenesis by Stimulating Necrosis
Apoptosis is but one facet of the host-cell response to CVB3
infection, raising the question of whether other aspects of
pathogenesis could require p38 signaling (Carthy et al., 1998;
Yuan et al., 2003). In the original data set, overall CVB3 cyto-
toxicity was measured via tetrazolium reduction (see the
Experimental Procedures). However, this method was inade-
quate to read out cytotoxicity in the presence of signaling
perturbations, which could also affect proliferation and metab-
olism. We therefore switched to a fluorescent amine-reactive
dye that intensely labels cells with compromised plasma-
membrane integrity irrespective of the mechanism of cell death
(Perfetto et al., 2006).
We found that CVB3 infection caused a dramatic increase in
the percentage of dye-labeled, nonviable cells as compared to
sham infection (Figures 5A–5D). The actual extent of cytotoxicity
was much greater than the flow-cytometry estimate (compare
Figures 5B and 5D), because many infected cells were so
damaged that they were unavoidably lost during the suspension
preparation. As with the earlier apoptosis experiments (Figure 4),
we found that SB pretreatment strongly decreased the extent of
CVB3-induced cytotoxicity, whereas PD did not have a signifi-
cant impact (p > 0.05) (Figures 5B–5F). Surprisingly, when SB
and PD were combined, we observed a clear improvement in
overall cell viability even though caspase activation was unaf-
fected under these conditions (Figure 4E and Figures 5B and
5G). The pronounced result of dual p38-ERK1/2 inhibition was
also reflected in significantly reduced titers of RVP (p < 0.001)
(Figures 6A and 6B). This raised the possibility that p38 could
control alternative death pathways that were distinct from
apoptosis but critically important for CVB3 pathogenesis.
We closely examined the morphology of CVB3-infected
cells by microscopy and noted a mixture of phenotypes indica-
tive of discrete single-cell outcomes (Figure 5D). Some cells
had a rounded appearance with condensed nuclei, suggesting
an apoptotic fate. Others, however, remained fully spread and
had aberrant lamellipodia-like projections (Figure 5D, right).
These cells also had an intact nucleus along with intracellular
vesicles that remained dye impermeant. Our observations
suggested that a fraction of CVB3-infected cells undergo a vesic-
ulated form of cell death with certain hallmarks of necrosis (Yuan
et al., 2003).nc.
BA
*
*
CVB3 + SB CVB3 + PD CVB3 + SB + PD
C Sham
0 200 400 600 800 1000
Amine-reactive labeling
0
200
400
600
800
1000
S
S
C
-H
ei
gh
t
13.3%
P
er
ce
nt
 d
ye
 la
be
lin
g
Sham CVB3 CVB3
+SB
CVB3
+PD
CVB3
+SB+PD
CVB3D
Apop
Ves
E F G
14
0
DNA Non-viable
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of CVB3-Infected Cells Independently of
ERK1/2 Signaling
(A) Representative flow-cytometry profile of
CVB3-infected cardiomyocytes labeled with
amine-reactive dye. Dye-positive cells (pink) are
considered nonviable.
(B) SB and SB+PD inhibit CVB3-induced cyto-
toxicity.
(C–G) Representative images of amine-labeled
adherent CVB3-infected cardiomyocytes pre-
treated with SB, PD, or SB+PD. Right panel of (D)
shows an enlarged image highlighting vesicu-
lated-necrotic cells (ves) and apoptotic cells
(apop).
Cells were pretreated with SB203580 (SB, 20 mM),
PD184352 (PD, 2 mM), or SB+PD for 1 hr and in-
fected with sham or CVB3 at moi = 9. Cells were
labeled with amine-reactive dye andmonitored by
flow cytometry or fluorescence microscopy. For
(B), data are shown as the mean ± SEM of four
biological replicates. Asterisk indicates p < 0.05
by Welch’s one-sided t test. For (C)–(G), scale bar
is 20 mm.
Cell Host & Microbe
ERK-p38 Coordination of CVB3-Induced Cell DeathTo determine whether CVB3 infection was associated with
biochemical readouts of necrosis, we examined the chromatin
protein HMGB1, which is released extracellularly by necrotic
cells (Scaffidi et al., 2002). We validated the marker by
stimulating cardiomyocyte necrosis with hydrogen peroxide
and observing pronounced HMGB1 release (Figure S5A). Impor-
tantly, we found that HMGB1 was clearly detected in superna-
tants from CVB3-infected cells (Figure 6C). HMGB1 release
was unaffected by the apoptosis inhibitor DEVD-CHO but was
slightly reduced by the necrosis inhibitor Necrostatin-1, likely
as a result of CVB3-induced autocrine TNF signaling (Degterev
et al., 2005; Garmaroudi et al., 2010). Thus, HMGB1 is a reliable
marker of necrosis stimulated by CVB3.
Upon p38 inhibition with SB or BIRB, we observed near-
complete blockade of HMGB1 release, suggesting potent
inhibition of necrosis (Figure 6D and Figure S5B). Conversely,
necrosis was negligibly affected in CVB3-infected cells
treated with PD to inhibit ERK1/2, consistent with the earlier
labeling results (Figures 5B and 5F and Figure 6E). In stark
contrast to the apoptotic readouts (Figure 4E), we did not
observe any reversion of necrosis when CVB3-infected cells
were pretreated with PD + SB (Figure 6F). Last, to test whether
p38 signaling was sufficient to drive virus-induced necrosis,
we returned to the inducible MKK6-EE cells and found that
DOX treatment substantially augmented HMGB1 release
during CVB3 infection (Figure 6G). We conclude that p38
signaling is a critical component of a necrosis pathway, which
promotes CVB3 propagation independently of ERK-dependent
apoptosis.Cell Host & Microbe 13, 67–76DISCUSSION
Viruses such as CVB3 activate many
host-cell signaling pathways and evoke
many host-cell responses. Our study
here began with a holistic approach tomonitor these events dynamically and as a function of CVB3 titer.
By analyzing the data to make quantitative predictions of host-
cell outcome, we quickly converged on ERKs and p38 as key
pathways for CVB3 pathogenesis. Early-phase ERK1/2 activa-
tion stems directly from CVB3 docking to host membranes,
whereas late-phase activation occurs due to cleavage of
upstream signaling molecules by viral proteases (Huber et al.,
1999; Luo et al., 2002). Late-phase p38 and ERK5 signaling
probably lies downstream of autocrine proinflammatory cyto-
kines, which are induced during the final stages of the viral life
cycle (Figure S6) (Garmaroudi et al., 2010). Despite differences
in activation, our work here shows that ERKs and p38 are
strongly interconnected (Figure 7). These dependencies are
important for interpreting the results of ‘‘single-pathway’’ pertur-
bations that propagate through the network (Luo et al., 2002; Si
et al., 2005).
Notably, we were able to uncover a role for ERK5 in CVB3
pathogenesis by modeling a data set that did not measure
ERK5 explicitly. We have shown elsewhere that quantitatively
accurate signaling measurements are critical for data-driven
models to reflect underlying biological mechanisms (Janes
et al., 2008; Janes and Yaffe, 2006). Our results here using
a pan-ERK p-ELISA indicate that measurements of specific
proteins may not be as important. This is encouraging, because
many modern signaling assays increase overall throughput
by relaxing the specificity constraints of traditional approaches
(Albeck et al., 2006).
Similarly, our work shows that agglomerated cell-outcome
data may be sufficient for viral-host modeling and discovering, January 16, 2013 ª2013 Elsevier Inc. 73
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Necrosis
(A and B) SB+PD markedly inhibits released viral
progeny (RVP) in CVB3-infected cells.
(C) HMGB1 is a reliable marker of CVB3-induced
necrosis.
(D–F) SB blocks CVB3-induced HMGB1 release
independently of ERK1/2 pathway inhibition with
PD. Note that PD does not affect the inhibition of
HMGB1 release caused by SB.
(G) p38 activation via DOX-inducible MKK6-EE
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(SB, 20 mM), PD184352 (PD, 2 mM), SB+PD,
Necrostatin-1 (Nec-1, 50 mM), or DEVD-CHO
(DEVD, 0.1 mM) for 1 hr and infected with sham or
CVB3 at moi = 9. For (A) and (B), RVP titers were
determined by plaque assay. For (D)–(G), culture
supernatants were concentrated and analyzed for HMGB1 release by immunoblotting. For (G), HL1 cells stably expressing doxycycline (DOX)-inducible MKK6-
EEwere infected with CVB3 atmoi = 1.5 and treatedwith 1 mg/ml DOX at 8 hr p.i. For (B), data are shown as themedian ± range of four biological replicates. Single
asterisk indicates p < 0.05 and double asterisk indicates p < 0.001 by Welch’s two-sided t test. See also Figure S5.
Cell Host & Microbe
ERK-p38 Coordination of CVB3-Induced Cell Deathoverlooked phenotypes. The importance of CVB3-induced
necrosis as a host-cell fate was revealed here without direct
necrotic readouts in the model (Figure 7). This information was
presumably embedded in the overall cytotoxicity measure,
which depends strongly on the level of necrosis (Figures 5A–
5D). Interestingly, the associated RVP titers appear to be
influenced by apoptosis and necrosis reciprocally. When
both apoptosis and necrosis are blocked upon p38 inhibition
with SB, there is a slight reduction in RVP. However, when
apoptosis is restored in p38-inhibited cells by blocking ERK1/2
hyperactivation, RVP is dramatically reduced (Figure 6B). Thus,
necrosis may be the preferred outcome for CVB3, which is
counteracted by the host-cell drive to die by apoptosis. To
isolate necrosis specifically requires targeting an upstream
mediator (p38) and resetting the other secondary consequences
of pathway inhibition (e.g., ERK1/2) (Figure 7). Such combinato-
rial antiviral strategies would be difficult to predict without
the aid of a systems model for the host-cell response to CVB3
infection.EXPERIMENTAL PROCEDURES
Plasmids
DOX-inducible MEK5 (Boehm et al., 2007) and MKK6-EE (Raingeaud et al.,
1996) were cloned by PCR into the Tet-tight entry vector pEN_TTmiRc2
(Shin et al., 2006). To generate MEK5-DD, S311 and T315 of MEK5 were both
mutated to glutamate by site-directed mutagenesis (QuikChange II XL, Strata-Figure 7. Model for ERK-p38 Signaling, Apoptosis, and Necrosis
Induced by CVB3
Dashed line indicates context-dependent inhibition of apoptosis by ERK1/2.
See also Figure S6.
74 Cell Host & Microbe 13, 67–76, January 16, 2013 ª2013 Elsevier Igene). All entry vectors were verified by sequencing, and lentiviral vectors were
cloned by LR recombination into pSLIK neo (Shin et al., 2006). pLKO.1 puro
shERK5 lentiviral vectors (TRCN0000023234 and TRCN0000023236) were
obtained from Open Biosystems.
Cells and Viruses
HL1 cells were provided by Dr. William Claycomb (Louisiana State University
Health Sciences Center, NewOrleans, USA) (Claycomb et al., 1998). 293T cells
were obtained from ATCC. CVB3 (Kandolf strain) was propagated in HeLa
cells, and virus titers were determined by plaque assay. Retroviruses and lenti-
viruses were packaged as previously described (Wang et al., 2011). Stably
transduced HL1 cells were selected with 4 mg/ml puromycin or 150 mg/ml
G418 until control plates had cleared.
Viral Infection and Perturbations
HL1 cells were sham infected with PBS or infected with CVB3 at moi 0.5, 1.5,
4.5, 9, or 18, and cell extracts were prepared at 0, 0.17, 1, 8, 16, and 24 hr. For
perturbation experiments, the following chemical inhibitors were added 1 hr
before infection: SB203580 (20 mM, Tocris Biosciences), BIRB796 (5 mM, Sell-
eck Chemicals), XMD8-92 (5 mM, Axon Medchem), U0126 (20 mM, Tocris
Biosciences), PD184352 (2 mM, Santa Cruz Biotechnology), DEVD-CHO
(0.1 mM, EMD), and Necrostatin-1 (50 mM, Calbiochem).
Plaque Assays
CVB3 titers from triplicate cell supernatants were determined on monolayers
of HeLa cells by an agar overlay plaque assay as described elsewhere (Gar-
maroudi et al., 2010).
p-ELISA
Cell lysates were normalized to protein concentration and analyzed by
p-ELISA (Biosource) for the phosphorylation levels of Akt (S473), ATF2 (T69/
T71), CREB (S133), ERK1/2 (T185/Y187), GSK3b (S9), Hsp27 (S82), IkBa (S32),
and p38 MAPK (T180/Y182) according to the manufacturer’s instructions.
Caspase-3, Caspase-8, and Caspase-9 Activity Assays
Caspase activities were measured according to the manufacturer’s instruction
(R&D Systems) as described elsewhere (Si et al., 2005). Fluorescence was
measured at excitation and emission wavelengths of 485 nm and 535 nm,
respectively, using a Tecan GENios fluorescent reader.
Immunoblotting
Immunoblotting was performed as described previously (Garmaroudi et al.,
2010) with one of the following primary antibodies: anti-p-ERK1/2 (T202/Y204,
Cell Signaling, 1:1000), anti-p-ERK5 (T218/Y220, Cell Signaling, 1:1,000),
anti-p-p38 (T180/T182, Cell Signaling, 1:1,000), anti-p-MAPKAPK2 (T334, Cellnc.
Cell Host & Microbe
ERK-p38 Coordination of CVB3-Induced Cell DeathSignaling, 1:1,000), anti-VP1 (Dako, 1:1,000), anti-cleaved caspase-8 (Cell
Signaling, 1:1,000), anti-caspase-9 (Cell Signaling, 1:1,000), anti-caspase-3
(Cell Signaling, 1:1,000), anti-b-actin (Sigma, 1:5,000), anti-p-Akt (S473, Cell
Signaling, 1:1,000), anti-p-GSK3b (S9, Cell Signaling, 1:1,000), anti-p-ATF2
(T69/T71, Cell Signaling, 1:1,000), anti-p-CREB (S133, Cell Signaling, 1:1,000),
anti-p-IkBa (S32, Cell Signaling, 1:1,000), anti-p-Hsp27 (S82, Cell Signaling,
1:1,000), anti-p-RSK (T359/S363, 1:1,000), anti-MEK5 (StressGen, 1:1,000),
anti-HA (Roche, 1:1,000), anti-HMGB-1 (Epitomics, 1:1,000), anti-p-MEF2A
(T312, Abcam, 1:1,000), anti-cleaved caspase-8 (Cell Signaling, 1:1,000), or
anti-tubulin (Cell Signaling, 1:5000 or Abcam, 1:20,000) for 1 hr or overnight,
followed by incubation for 1 hr with horseradish peroxidase-conjugated
secondary antibodies (Santa Cruz) or infrared dye-conjugated secondary anti-
bodies (Li-Cor). Immunoreactive bands were visualized by enhanced chemilu-
minescence (Pierce, Rockford, IL) on ChemiGenius2 or ChemiDoc MP
camera-based detection systems or by infrared fluorescence on an Odyssey
infrared imaging system. Where indicated, band intensities were quantified
by densitometry with ImageJ, and all blotting results were replicated with at
least one additional set of independent biological samples.
Cell Viability Assays
HL1 cells were grown in 12-well plates and infected with CVB3 (moi = 9) for 16
and 24 hr after pretreatment with inhibitors. The MTS solutions (1:5) were
added to wells for 2.5 hr and then transferred to 96-well plates. Cell viabilities
of infected and noninfected cells were assessed by MTS assay (CellTiter 96;
Promega, Inc., Madison, WI). Amine-reactive labeling was performed with
the LIVE/DEAD fixable violet dead stain (Invitrogen) according to the manufac-
turer’s recommendations. For flow cytometry, cells were labeled in suspen-
sion, washed with PBS + 0.1% Tween-20, and analyzed on a BD FACSCalibur
equipped with 407 nm violet laser excitation. For microscopy, adherent cells
were labeled, washed with PBS, permeabilized with 0.3% Triton X-100 in
PBS, and counterstained with DRAQ-5 before imaging by widefield micros-
copy as described previously (Wang et al., 2011).
Partial Least-Squares Regression
Phosphoproteins (predictor variables) and readouts (response variables) were
standardized as Z scores, and the phosphoprotein time course was time inte-
grated over early (0–8 hr) and late (8–24 hr) phases. Partial least-squares
regression was performed with the ‘‘plsregress’’ function in MATLAB by stan-
dard approaches (Janes et al., 2005; Janes and Yaffe, 2006). The stability of
the model was assessed by 5-fold leave-one-out crossvalidation.
Statistical Analysis
All hypothesis testing was performed with Welch’s one- or two-sided t test at
a significance level of a = 0.05.
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